Generic Adrenalin Availability
Last updated on May 9, 2024.
See also: Generic Adrenaclick
Adrenalin is a brand name of epinephrine, approved by the FDA in the following formulation(s):
ADRENALIN (epinephrine - solution;intravenous)
-
Manufacturer: ENDO OPERATIONS
Approval date: April 21, 2023
Strength(s): 2MG/250ML (8MCG/ML) [RLD], 4MG/250ML (16MCG/ML) [RLD], 5MG/250ML (20MCG/ML) [RLD], 8MG/250ML (32MCG/ML) [RLD], 10MG/250ML (40MCG/ML) [RLD]
Has a generic version of Adrenalin been approved?
No. There is currently no therapeutically equivalent version of Adrenalin available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Adrenalin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Epinephrine compositions and containers
Patent 10,653,646
Issued: May 19, 2020
Inventor(s): Akasapu Prem Sagar & Soppimath Kumaresh & Puri Reema Ajitkumar & Ilitchev Iouri V. & Patel Milan & Tendulkar Pooja H.
Assignee(s): Nevakar Inc.The inventive subject matter provides ready-to-administer, preferably anti-oxidant free, epinephrine compositions with improved stability, and methods for preparing the same. Contemplated compositions can be packaged using blow-fill-seal technology or packaged into flexible IV bags and maintain degradation of the epinephrine at a level of less than 5 wt % when stored over at least one months at between 2-40° C.
Patent expiration dates:
- March 21, 2039✓
- March 21, 2039
-
Epinephrine compositions and containers
Patent 11,083,698
Issued: August 10, 2021
Inventor(s): Akasapu Prem Sagar & Soppimath Kumaresh & Puri Reema Ajitkumar & Ilitchev Iouri V. & Patel Milan & Tendulkar Pooja H.
Assignee(s): NEVAKAR INC.The inventive subject matter provides ready-to-administer, preferably anti-oxidant free, epinephrine compositions with improved stability, and methods for preparing the same. Contemplated compositions can be packaged using blow-fill-seal technology or packaged into flexible IV bags and maintain degradation of the epinephrine at a level of less than 5 wt % when stored over at least one months at between 2-40° C.
Patent expiration dates:
- March 21, 2039✓
- March 21, 2039
-
Epinephrine compositions and containers
Patent 11,207,280
Issued: December 28, 2021
Inventor(s): Akasapu Prem Sagar & Soppimath Kumaresh & Puri Reema Ajitkumar & Ilitchev Iouri V. & Patel Milan & Tendulkar Pooja H.
Assignee(s): Nevakar Injectables Inc.The inventive subject matter provides ready-to-administer, preferably anti-oxidant free, epinephrine compositions with improved stability, and methods for preparing the same. Contemplated compositions can be packaged using blow-fill-seal technology or packaged into flexible IV bags and maintain degradation of the epinephrine at a level of less than 5 wt % when stored over at least one months at between 2-40° C.
Patent expiration dates:
- March 21, 2039✓
- March 21, 2039
More about Adrenalin (epinephrine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Latest FDA alerts (3)
- Side effects
- Dosage information
- During pregnancy
- Drug class: adrenergic bronchodilators
- Breastfeeding
- En español
Patient resources
- Adrenalin drug information
- Adrenalin (Epinephrine Inhalation) (Advanced Reading)
- Adrenalin (Epinephrine Injection) (Advanced Reading)
- Adrenalin (Epinephrine Injection Solution)
Other brands
EpiPen, Auvi-Q, Primatene Mist, Adrenaclick, ... +4 more
Professional resources
Other brands
EpiPen, Auvi-Q, Primatene Mist, Adrenaclick, ... +3 more
Other formulations
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.